Dr. Darren Feldman on the Drawbacks of Dose Intensification for Advanced Germ Cell Tumors
​Darren Feldman, MD, discusses dose intensification in patients with advanced germ cell tumors who are not responding to BEP chemotherapy.
Darren Feldman, MD, assistant attending physician for the Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dose intensification in patients with advanced germ cell tumors who are not responding to BEP chemotherapy (bleomycin, etoposide, cisplatin).
Feldman says one study, dubbed GETUG 13, looked at patients with a slow biomarker decline after their first cycle of BEP. He says patients enrolled in the study had a better progression free survival (PFS) rate when switched to a more intensive regimen of chemotherapy, as opposed those who continued on with a standard dose.
